A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients with Advanced Cancer

We conducted a phase I study to assess safety, pharmacokinetics, pharmacodynamics and activity of lonafarnib plus gemcitabine. Subjects received oral lonafarnib twice daily and gemcitabine on days 1, 8 and 15 every 28 days; multiple dose levels were explored. Lonafarnib had no apparent effect on gem...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wong, Nan Soon, Meadows, Kellen L., Rosen, Lee S., Adjei, Alex A., Kaufmann, Scott H., Morse, Michael A., Petros, William P., Zhu, Yali, Statkevich, Paul, Cutler, David L., Meyers, Michael L., Hurwitz, Herbert I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4101887/
https://ncbi.nlm.nih.gov/pubmed/22011284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/07357907.2011.621912
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller